- Home
- CYH vs EOLS Comparison
CYH vs EOLS Comparison
Compare CYH & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- EOLS
- Stock Information
- Founded
- CYH 1985
- EOLS 2012
- Country
- CYH United States
- EOLS United States
- Employees
- CYH N/A
- EOLS N/A
- Industry
- CYH Hospital/Nursing Management
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- EOLS Health Care
- Exchange
- CYH Nasdaq
- EOLS Nasdaq
- Market Cap
- CYH 410.5M
- EOLS 444.0M
- IPO Year
- CYH 1991
- EOLS 2018
- Fundamental
- Price
- CYH $3.15
- EOLS $6.92
- Analyst Decision
- CYH Hold
- EOLS Strong Buy
- Analyst Count
- CYH 8
- EOLS 4
- Target Price
- CYH $3.73
- EOLS $21.25
- AVG Volume (30 Days)
- CYH 2.1M
- EOLS 2.0M
- Earning Date
- CYH 10-23-2025
- EOLS 11-05-2025
- Dividend Yield
- CYH N/A
- EOLS N/A
- EPS Growth
- CYH N/A
- EOLS N/A
- EPS
- CYH 2.47
- EOLS N/A
- Revenue
- CYH $12,644,000,000.00
- EOLS $285,823,000.00
- Revenue This Year
- CYH $0.06
- EOLS $13.39
- Revenue Next Year
- CYH $2.13
- EOLS $26.85
- P/E Ratio
- CYH $1.27
- EOLS N/A
- Revenue Growth
- CYH 0.74
- EOLS 15.10
- 52 Week Low
- CYH $2.24
- EOLS $5.71
- 52 Week High
- CYH $4.47
- EOLS $17.12
- Technical
- Relative Strength Index (RSI)
- CYH 43.07
- EOLS 50.05
- Support Level
- CYH $2.90
- EOLS $6.53
- Resistance Level
- CYH $3.93
- EOLS $7.67
- Average True Range (ATR)
- CYH 0.18
- EOLS 0.48
- MACD
- CYH -0.10
- EOLS -0.03
- Stochastic Oscillator
- CYH 22.93
- EOLS 38.74
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.